Source: Resumos. Conference titles: Therapies for viral hepatitis. Unidade: FM
Subjects: HEPATITE CRÔNICA (TERAPIA), HEPATITE B (TERAPIA), ANTI-INFECCIOSOS (APLICAÇÕES TERAPÊUTICAS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOLLANO, J et al. Entercaver is well-tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naive and lamivudine-refractory patients. 2004, Anais.. Boston: Faculdade de Medicina, Universidade de São Paulo, 2004. . Acesso em: 02 out. 2024.APA
Sollano, J., Schiff, E., Carrilho, F. J., Raptopoulo-Gigi, M., Cooney, E., Hindes, R., et al. (2004). Entercaver is well-tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naive and lamivudine-refractory patients. In Resumos. Boston: Faculdade de Medicina, Universidade de São Paulo.NLM
Sollano J, Schiff E, Carrilho FJ, Raptopoulo-Gigi M, Cooney E, Hindes R, Cross A, DeHertongh D. Entercaver is well-tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naive and lamivudine-refractory patients. Resumos. 2004 ;[citado 2024 out. 02 ]Vancouver
Sollano J, Schiff E, Carrilho FJ, Raptopoulo-Gigi M, Cooney E, Hindes R, Cross A, DeHertongh D. Entercaver is well-tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naive and lamivudine-refractory patients. Resumos. 2004 ;[citado 2024 out. 02 ]